An experimental treatment significantly improved progression-free survival in patients with neuroblastoma at high risk for recurrence, including many young children, researchers from the Children’s Oncology Group reported last week. Speaking at a press briefing sponsored by the American Society of Clinical Oncology, the trial’s lead investigator, Dr. Alice Yu from the University of California, San Diego, said the finding makes the treatment—an antibody-based immunotherapy—“the new standard of care” for patients with high-risk neuroblastoma. Read more > >
By Dr. Robert Yarchoan
NCI has played a critical role in HIV- and AIDS-related research from the day in 1981 when one of the first AIDS patients was admitted to the NCI Metabolism Branch. NCI's advances in AIDS research, in part, resulted from the Institute's long-term commitment to research on the interrelationship between viruses and cancer. Read more > >
- Bevacizumab Approved for Recurrent Glioblastoma Brain Cancer
- In Memoriam: NCI's Dr. John Brady
- Deadline Approaching for DCLG Nominations
- IOTF Fellowship Program Seeks Applicants
- Women's Health Hearing and Workshop Series Continues
- NCI Cancer Bulletin Writer Wins NAGC Award
- Meet NCI Experts at ASCO
- Smokefree Women Web Site Launched
- NCI Publications Locator Web Site Improved
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.